In a major regulatory milestone, Hikal Ltd. has announced that its Active Pharmaceutical Ingredient (API) manufacturing facility at Jigani, Bengaluru has received Good Manufacturing Practices (GMP) certification from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA). This certification, granted in July 2025, marks a strategic leap for Hikal’s global expansion, especially into Japan’s highly regulated pharmaceutical market.
Key Highlights from the Certification Announcement:
- Jigani Unit receives PMDA Japan GMP certification
- Certification covers multiple APIs and intermediates
- Facility already approved by US FDA, ANVISA Brazil, and other global regulators
- Opens access to Japan’s $100 billion pharmaceutical market
- Strengthens Hikal’s position as a preferred global CDMO partner
Facility Overview and Regulatory Track Record:
Hikal’s Jigani site, located 30 km from Bengaluru, comprises two manufacturing units:
- Unit I spans 87,700 square meters and is US FDA-approved for cGMP intermediates and APIs
- Unit II covers 8,114 square meters and supports advanced intermediate production
Both units are frequently audited by multinational innovator companies from the US, Europe, and Japan. The facility has previously cleared inspections from ANVISA Brazil and US FDA, with zero critical observations, reinforcing its reputation for quality and compliance.
Strategic Significance of PMDA Certification:
Japan’s PMDA certification is among the most stringent in the world, requiring rigorous documentation, process validation, and quality assurance protocols. With this approval:
- Hikal can now export APIs directly to Japanese pharmaceutical companies
- The company gains access to Japan’s high-margin generics and specialty drug segments
- It enhances credibility with other Asian regulators, including Korea’s KFDA and China’s NMPA
- Strengthens Hikal’s ability to file Japanese Drug Master Files (JDMFs) for key molecules
This certification also aligns with Hikal’s broader strategy to expand its footprint in regulated markets and deepen partnerships with global innovators.
Product Portfolio and Therapeutic Reach:
The Jigani unit manufactures a wide range of APIs and intermediates across therapeutic categories such as:
- Anti-diabetic (e.g., Vildagliptin, Canagliflozin)
- Anti-depressant (e.g., Venlafaxine, Bupropion)
- Anti-hypertensive (e.g., Olmesartan)
- Anti-psychotic and anti-convulsant drugs
Hikal’s robust pipeline includes molecules with USDMF, EDMF, CEP, and now JDMF support, enabling seamless regulatory filings across geographies.
Operational Excellence and Sustainability:
The Jigani site is equipped with:
- In-house solvent recovery and wastewater treatment facilities
- ISO 9001, ISO 14001, and OHSAS 18001 certifications
- PRINCE2-trained project managers for global client coordination
These capabilities ensure not just compliance but also sustainable and scalable manufacturing for global supply chains.
Industry Impact and Future Outlook:
With the PMDA certification, Hikal joins a select group of Indian pharma manufacturers with multi-jurisdictional GMP approvals. This positions the company to:
- Accelerate contract development and manufacturing (CDMO) deals with Japanese firms
- Expand its share in Asia’s growing generics and biosimilars market
- Leverage regulatory momentum to file additional DMFs and launch new products
The certification also comes at a time when Japanese pharma companies are increasingly outsourcing API production to India, driven by cost efficiency and quality assurance.
Conclusion:
Hikal’s PMDA Japan GMP certification is more than a regulatory win—it’s a strategic gateway to one of the world’s most lucrative and quality-conscious pharma markets. With a proven track record, diversified portfolio, and global compliance credentials, Hikal is poised to scale new heights in its international growth journey.
Sources: Indian Pharma Post, Hikal Ltd Official Website, Business Standard, Hikal Facilities Overview, Investing.com India
